Categories
Tags
Abbott Advertising AstraZeneca Barack Obama Biotech Biotechnology and Pharmaceuticals Bristol Myers Squibb business Cancer Clinical trial conference Deal Eli Lilly European Commission European Union Facebook FDA Food and Drug Administration Genentech generics GlaxoSmithKline Google GSK HBA Health Health care Johnson & Johnson layoffs Lilly Marketing Merck Novartis Pfizer Pharma Pharmaceutical drug pharmaceutical industry Research and development Roche sales force Sanofi-Aventis Schering Plough Twitter U.S. Food and Drug Administration United States Wyeth
Technology News
BioPharm News
Tag Archives: Bristol Myers Squibb
Judge Throws The Book At Former Bristol-Myers Squibb Exec
Media wordsmiths are competing to outdo one another today in punny reporting on the news that ex-BMS exec Andrew Bodnar has been sentenced to write a book about the role he played in the firm’s 2006 reverse-payments case over generic Plavix.
“Pen-ance: Bristol-Myers Exec Gets Two Years of Hard Writing,†The Wall Street Journal Law Blog [...]
Posted in Legal Also tagged Andrew Bodnar, BMS, Federal Bureau of Investigation, Judge Urbina, Park Avenue, Plea, Wall Street Journal, White-collar crime Leave a comment
Gilead Making a Bundle
Gilead Sciences has once again proven that independent biotechs can innovate with the best of Big Pharma. The Silicon Valley company’s wizardry at weaving multiple drugs into a single weft enabled it to overthrow GlaxoSmithKline as king of HIV in 2007. Yesterday, at the 16th annual Congress of Retroviruses and Opportunistic Infections (CROI), the biotech [...]
Lilly Puts Up $6.5 Billion for ImClone
Lilly broke the news Monday morning that ImClone had accepted its offer to acquire the biotech firm for $6.5 billion or $70 per share—Lilly’s largest acquisition ever.
With this purchase Lilly gains control of ImClone’s blockbuster, targeted cancer agent Erbitux, which is marketed for second- and third-line colon cancer and refractory head and neck cancer.
ImClone also [...]

AstraZeneca, BMS Announce Layoffs and Buyouts